Cite
HARVARD Citation
Eckstein, O. et al. (2022). Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. Journal of clinical oncology. 40 (20), pp. 2235-2245. [Online].